Skip to main content

Table 2 Propensity score method was used to explore the association between Blastocystis hominis infection and CD4+ T immunological status, HIV virological status, and treatment interruption

From: Impact factors of Blastocystis hominis infection in persons living with human immunodeficiency virus: a large-scale, multi-center observational study from China

Variables

Subgroups

Matching ratio

Caliper

Blastocystis hominis

negative

n

Blastocystis hominis

positive

n

Wald χ2

P value

OR (95% CIs)

CD4+ T immunological statusa

No immunosuppression (> 500 cells/μl)

1:1

0.01

55

55

14.406

0.002

1 (reference)

 

Mild immunosuppression (350–500 cells/μl)

4.194 (1.195–14.716)

 

Moderate immunosuppression (200–350 cells/μl)

8.095 (2.372–27.623)

 

Severe immunosuppression (≤ 200 cells/μl)

7.857 (2.352–26.251)

CD4+ T immunological statusa

No immunosuppression (> 500 cells/μl)

1:1

0.02

57

57

18.868

< 0.001

1 (reference)

 

Mild immunosuppression (350–500 cells/μl)

4.206 (1.199–14.759)

 

Moderate immunosuppression (200–350 cells/μl)

9.952 (2.945–33.631)

 

Severe immunosuppression (≤ 200 cells/μl)

9.308 (2.786–31.097)

CD4+ T immunological statusa

No immunosuppression (> 500 cells/μl)

1:2

0.01

44

88

18.586

< 0.001

1 (reference)

 

Mild immunosuppression (350–500 cells/μl)

10.062 (1.218–83.115)

 

Moderate immunosuppression (200–350 cells/μl)

147.072 (11.600–1864.698)

 

Severe immunosuppression (≤ 200 cells/μl)

115.786 (10.087–1329.131)

CD4+ T immunological statusa

No immunosuppression (> 500 cells/μl)

1:2

0.02

49

98

26.335

< 0.001

1 (reference)

 

Mild immunosuppression (350–500 cells/μl)

3.972 (1.108–14.238)

 

Moderate immunosuppression (200–350 cells/μl)

13.684 (3.962–47.268)

 

Severe immunosuppression (≤ 200 cells/μl)

12.381 (3.679–41.664)

HIV virological statusb

Full virological suppression (< 50 copies/ml)

1:1

0.01

55

55

16.341

< 0.001

1 (reference)

 

Low level viraemia (51–999 copies/ml)

11.062 (1.852–66.073)

 

Virological failure (> 1000 copies/ml)

22.191 (4.874–101.031)

HIV virological statusb

Full virological suppression (< 50 copies/ml)

1:1

0.02

57

57

18.236

< 0.001

1 (reference)

 

Low level viraemia (50–999 copies/ml)

12.082 (2.199–66.367)

 

Virological failure (> 1000 copies/ml)

24.928 (5.695–109.110)

HIV virological statusb

Full virological suppression (< 50 copies/ml)

1:2

0.01

47

94

22.522

< 0.001

1 (reference)

 

Low level viraemia (51–999 copies/ml)

24.000 (5.186–111.077)

 

Virological failure (> 1000 copies/ml)

31.304 (7.537–130.013)

HIV virological statusb

Full virological suppression (< 50 copies/ml)

1:2

0.02

49

98

26.961

< 0.001

1 (reference)

 

Low level viraemia (51–999 copies/ml)

18.429 (4.989–68.071)

 

Virological failure (> 1000 copies/ml)

22.567 (6.958–73.191)

Treatment interruption c

Treatment interruption (No)

1:1

0.01

55

55

13.274

0.001

1 (reference)

 

Treatment interruption (Yes)

14.000 (3.335–58.768)

Treatment interruption c

Treatment interruption (No)

1:1

0.02

57

57

11.814

< 0.001

1 (reference)

 

Treatment interruption (Yes)

12.500 (2.961–52.773)

Treatment interruption c

Treatment interruption (No)

1:2

0.01

46

92

17.377

 < 0.001

1 (reference)

 

Treatment interruption (Yes)

13.110 (3.910–43.963)

Treatment interruption c

Treatment interruption (No)

1:2

0.02

49

98

20.501

< 0.001

1 (reference)

 

Treatment interruption (Yes)

9.261 (3.534–24.273)

  1. aAdjusted for age (≥ 60 years vs < 60 years), body mass index (< 18.5, 18.5–24.9, > 25.0), family members (< 3 individuals vs ≥ 3 individuals), gender, residence, region, occupation, nationality, marital status, educational level, toilet type, water supply, drinking water, livestock, pet, HIV infection route, newly infection, HIV VL, treatment interruption
  2. bAdjusted for age (≥ 60 years vs < 60 years), body mass index (< 18.5, 18.5–24.9, ≥ 25.0 kg/m2), family members (< 3 individuals vs ≥ 3 individuals), gender, residence, region, occupation, nationality, marital status, educational level, toilet type, water supply, drinking water, livestock, pet, HIV infection route, newly infection, CD4+ T cell counts, duration of treatment interruption in HARRT. c: adjusted for age (≥ 60 years vs < 60 years), body mass index (< 18.5, 18.5–24.9, ≥ 25.0 kg/m2), family members (< 3 individuals vs ≥ 3 individuals), gender, residence, region, occupation, nationality, marital status, educational level, toilet type, water supply, drinking water, livestock, pet, HIV infection route, newly infection, CD4+ T cell counts, HIV VL
  3. CIs: Confidence intervals. HAART: Highly active antiretroviral therapy. HIV: Human immunodeficiency virus. OR: Odds ratio. VL: Viral load
Back to article page

Infectious Diseases of Poverty

ISSN: 2049-9957

Contact us